



The Voice of *Urologic Oncology* in Canada

Canadian Urological Association

La voix de *l'uro-oncologie* au Canada

# CUA Call-to-Action Meeting: Advanced Prostate Cancer (mCSPC)

## AGENDA

Saturday, October 14, 2023

Westin Harbour Castle Hotel

Room: Pier 2 & 3


Toronto, ON

[cua.org](http://cua.org)



The Voice of **Urologic Oncology** in Canada  
Canadian **Urological Association**  
La voix de **l'uro-oncologie** au Canada

# CUA Tool Card & Treatment Algorithm for the Treatment of Metastatic Castration-Sensitive Prostate Cancer (mCSPC)



## Legend

Level 1 Evidence, Strong

Level 1 Evidence, Weak

Level 2 Evidence, Strong

Level 2 Evidence, Weak

Level 3 Evidence, Strong

Level 3 Evidence, Weak

Expert Opinion

Levels of recommendation based on the 2022 Canadian Urological Association-Canadian Urologic Oncology Group Guideline: Metastatic Castration-Naive and Castration-Sensitive Prostate Cancer Update

\* High-volume is defined by the presence of visceral metastases or  $\geq 4$  bone lesions with  $\geq 1$  beyond the vertebral bodies and pelvis; low-volume is defined as all other metastatic castration-naive and castration-sensitive prostate cancer.

\*\* In patients who can safely tolerate docetaxel and in whom docetaxel is felt to be appropriate, triplet regimen should be considered as a treatment option.

### Contributing Authors:

Kim N. Chi  
Sebastien Hotte  
Tamim Niazi  
Frédéric Pouliot  
Ricardo Rendon  
Fred Saad  
Urban Emmenegger

### References:

So AI, Chi K, Danielson B, et al. UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer. *Can Urol Assoc J* 2022; 16(12):E581-9. doi: 10.5489/auaj.8148

Date of last update: 2023-06-19

All educational materials from the Canadian Urological Association (CUA) have undergone approval process and are the intellectual property of the CUA. Reproduction of these documents in any form requires the express written consent of the CUA. For any permission requests, comments/feedback, or to enquire about program content, please contact: [tiffany.pizioli@cua.org](mailto:tiffany.pizioli@cua.org).

**Saturday, October 14, 2023 • 08:00-15:35 ET**

<b>08:00 - 08:30</b>	<b>Breakfast Buffet</b>	<b>11:45 - 11:50</b>	<b>Q &amp; A</b>
<b>08:30 - 08:40</b>	<b>Introduction</b>	<b>11:50 - 12:20</b>	<b>Prevention and management of ADT side effects</b> Ricardo Rendon
<b>08:40 - 09:10</b>	<b>mCSPC diagnosis and treatment Flow primer</b> Ricardo Rendon	<b>12:20 - 13:00</b>	<b>Lunch Buffet</b>
<b>09:10 - 09:15</b>	<b>Q &amp; A</b>	<b>13:00 - 13:30</b>	<b>Somatic and genetic testing: Why, when, and how?</b> Justin Lorentz
<b>09:15 - 09:45</b>	<b>mCSPC treatment intensification: Review of the data and stratification</b> Aly-Khan Lalani	<b>13:30 - 13:35</b>	<b>Q &amp; A</b>
<b>09:45 - 09:55</b>	<b>Q &amp; A</b>	<b>13:35 - 14:05</b>	<b>PSMA PET</b> Katherine Zukotinski
<b>09:55 - 10:35</b>	<b>Managing the burden of intensification in academic and community settings</b> Bobby Shayegan: Academic setting Troy Sitland: Community setting	<b>14:05 - 14:10</b>	<b>Q &amp; A</b>
<b>10:35 - 10:40</b>	<b>Q &amp; A</b>	<b>14:10 - 14:40</b>	<b>Oligometastatic disease</b> Andrew Loblaw
<b>10:40 - 10:50</b>	<b>Health Break</b>	<b>14:40 - 14:45</b>	<b>Q &amp; A</b>
<b>10:50 - 11:20</b>	<b>Followup strategies and side effect management</b> Bobby Shayegan	<b>14:45 - 15:30</b>	<b>Case discussions</b> Aly-Khan Lalani Andrew Loblaw Ricardo Rendon Bobby Shayegan Chris Wallis
<b>11:20 - 11:25</b>	<b>Q &amp; A</b>	<b>15:30 - 15:35</b>	<b>Wrap-up &amp; Adjournment</b>
<b>11:25 - 11:45</b>	<b>Sequencing after progression</b> Aly-Khan Lalani		

**Thanks to the generous support of our meeting sponsors**




This event is accredited as a Section 1 group learning activity as defined by the Maintenance of certification of the Royal College of Physicians and Surgeons of Canada (RCPC), for a maximum of 5 hours of Section 1 credits.



# mCSPC Treatment Decision Support Tool

An easy-to-use, online Decision Support Tool that provides guideline-directed advice to physicians, with the goal of achieving optimal patient outcomes. Full results are printable for quick reference and easy placement into EMR systems.



Access on UROpedia Canada

**UROpedia**<sup>™</sup>  
CANADA

[cua.org](http://cua.org)

**Corporate Office**

185 Dorval Avenue, Suite 401 • Dorval (QC) Canada H9S 5J9

[cua.org](http://cua.org)